MedPageToday -- Treatment with tanezumab, a monoclonal antibody that targets nerve growth factor, led to significant improvements in osteoarthritis knee pain, a phase II proof-of-concept study showed.
MedPageToday -- Treatment with tanezumab, a monoclonal antibody that targets nerve growth factor, led to significant improvements in osteoarthritis knee pain, a phase II proof-of-concept study showed.
